RE
RemeGen Co., Ltd.
REGMF · OTC
$9.96 -8.87% (-$0.97)
1M +4.40%
Market Cap ¥37.6B
P/E Ratio 6.50x
Div. Yield -
ROE 127.36%
Bulios Fair Price
$12.31
23.6% upside
Current Price
$9.96
Undervalued Fair Value Overvalued
According to Bulios Fair Price, REGMF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
86 /100
Cheap P/E 6.50x
EV/EBITDA 7.23x
P/S 4.73x
Growth
78 /100
Growing Rev. growth 60.38%
Book val. growth 10.17%
EPS growth N/A
Profitability
100 /100
Strong Gross margin 92.68%
Net margin 72.71%
Op. margin 61.13%
Quality
95 /100
Excellent ROIC 56.34%
ROE 127.36%
ROA 58.71%
Debt
100 /100
Low Debt/Equity 0.04x
Current ratio 4.86x
Int. coverage 106.63x
Stability
34 /100
Moderate Beta 0.45x
Rev. volatility 22.62%
EPS volatility 101.11%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about REGMF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jian Min Fang
Employees
3,048
Headquarters
Yantai
Upcoming events
04 NOV
Earnings
Upcoming earnings report